CDC ends universal newborn hepatitis B vaccine recommendations
The US Centers for Disease and Prevention (CDC) no longer recommends that all US newborns receive the hepatitis B vaccine,…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Sanofi signs pair of billion-dollar biotech deals to bolster pipeline
Following the disappointment of a multiple sclerosis (MS) trial readout this week, Sanofi has signed a pair of deals in…
-
First gonorrhoea antibiotics in decades herald new era of treatment
Approvals in the US for a pair of new oral antibiotics for gonorrhoea represent a significant improvement in efforts to…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
EU inches closer to new pharma legislation amid competitiveness drive
Pharmaceutical companies marketing products in Europe could be set for a commercial boost, after legislators have agreed on a new…
-
Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify
Even with Johnson & Johnson’s (J&J) $14.6bn buyout of Intra-Cellular Therapies in January setting a strong deal-making tone, 2025 still…
-
Moderna signs deal worth up to $503m with Nanexa
Moderna has entered a licence agreement with Nanexa to add tailored release profiles to its injectable drugs. According to the…
-
Cell and gene therapy investment strategy pivots as funding dries up
Companies looking to push into the gene therapy (CGT) sector are navigating a more selective funding landscape amid a wider…
-
BIOSECURE Act set for Congress vote after inclusion in annual defence bill
After years in legislative limbo, the BIOSECURE Act – albeit with a softer framework – is poised to enter the…
-
Mirum to buy Bluejay for up to $820m in rare liver disease push
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver…